{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-005343","form_type":"8-K","ticker":"PMVP","cik":"0001699382","company_name":"PMV Pharmaceuticals, Inc.","filed_at":"2023-03-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.189765+00:00","generated_at":"2026-06-18T18:24:08.833261+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"PMV Pharma reports FY2022 net loss $73.3M; cash $243.5M; PC14586 update expected 2H 2023","bullets":["Net loss $73.3M in FY2022 vs $57.8M in FY2021; R&D expenses rose to $52.0M from $36.5M.","Cash, equivalents, and marketable securities $243.5M at Dec 31, 2022, down from $314.1M.","Phase 1/2 PYNNACLE study of PC14586 ongoing; first patient enrolled in combination arm with KEYTRUDA.","WIP-1 and R273H programs put on hold; projected cash runway extended to 1H 2025.","Appointed Kirsten Flowers and Carol Gallagher to Board; promoted Michael Carulli to SVP Finance."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-005343","json":"https://secwatch.observer/filing/0000950170-23-005343.json","markdown":"https://secwatch.observer/filing/0000950170-23-005343.md","text":"https://secwatch.observer/filing/0000950170-23-005343.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1699382/000095017023005343/0000950170-23-005343-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1699382/000095017023005343/pmvp-20230301.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T18:24:08.833261+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8dd4570b0b8d4e27189f8fb4eaa62d7e25e861dd","claim":"PMV Pharmaceuticals, Inc. reported the full year ended December 31, 2022 results: net income Net loss for the year ended December 31, 2022, was $73.3 million.","evidence_excerpt":"Net loss for the year ended December 31, 2022, was $73.3 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1699382/000095017023005343/0000950170-23-005343-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2022"},{"label":"Net income","value":"Net loss for the year ended December 31, 2022, was $73.3 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}